Companies are becoming more organised in their approach and the Index leaders are increasingly coming to view access as a strategic issue. Access to medicine has landed in more boardrooms.
The 2012 Index finds that more than 60% of companies now have direct board ownership of access to medicine and that more companies are setting meaningful targets. Among the highest-ranked companies, leadership is coming from the very top, and there’s an ever-increasing organisational focus. Dedicated access functions are being established and incentives to deliver access objectives are becoming more common, and are increasingly supported by performance management systems. For instance, Index leader GlaxoSmithKline has, since the last Index report in 2010, established a Developing Countries and Market Access unit as a department dedicated to access, bringing all its businesses in Least Developed Countries under one umbrella, supported by a new lower price/higher volume business model. Notably, the bonus system for managers in this new unit is structured in a fundamentally different way, to reward volume growth rather than profit growth. Three other companies in the top five - Johnson & Johnson, Sanofi and Gilead – as well as Eisai, have also created similar dedicated departments.